Compared to control groups with either no T cell transfer (Ctrl) or T cells transduced with an empty vector (Mock), CAR-T cells (CAR) exhibited potent anti-tumor activity, whereas CAR-T cells engineered to knockdown ADAM17 (CAR ADAM17 shRNA) had remarkably enhanced tumor eradication efficacy (Fig. 6c and supplementary Fig. 8f). Here, ADAM17 is linked to neoplasm.